ICMR

Outlook on the Enzyme Global Market to 2035: Players Include Adisseo, AB Enzymes, Amano Enzyme, BASF and Codexis - ResearchAndMarkets.com

Retrieved on: 
Friday, February 24, 2023
Health, Other Health, Diabetes, Glutamic acid, Food, ICMR, Protein, Cancer, Evaluation, Chronic pain, Indian Council of Medical Research, Sensation, Medical research, Public Health Foundation of India, Institute for Health Metrics and Evaluation, GMO, Pulse, Enzyme, Growth, Sciatica, MSG, Arthritis, Incidence, Type 2 diabetes, Prevalence, Fine chemical

Moreover, the high demand of enzymes in food and beverage industry is a key contributing factor for the market growth.

Key Points: 
  • Moreover, the high demand of enzymes in food and beverage industry is a key contributing factor for the market growth.
  • Moreover, the rising prevalence and incidence rates of chronic illnesses across the world is driving the growth of the enzyme at a substantial rate.
  • On the other hand, the immense concern related to the handling and safety issues of enzymes is constricting the market growth.
  • The global enzyme market is segmented into type, source, reaction type, and application.

Possible Breakthrough in Cardiovascular Disease Diagnostics for Europe and the European Union

Retrieved on: 
Friday, December 16, 2022
Peptide, Nanoparticle, Hereditary nonpolyposis colorectal cancer, SingHealth, Convergence (sustainability science), Degenerative disease, ICMR, Union, Prostate, Biomarker, Acute coronary syndrome, Patient, Hospital, Cardiovascular disease, FDA, Dengue fever, Death, Coronavirus Scientific Advisory Board (Turkey), Nanotechnology, Gold, Electronics, Machine learning, USD, Medical research, Pharmaceutical industry, Medical imaging, Science, Myoglobin, Malaria

Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers.

Key Points: 
  • Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers.
  • The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and is currently developing effective diagnostic assays.
  • The use of small peptides, conjugated with gold nanoparticles, allows a balance of high specificity and sensitivity, giving highly accurate and fast results.
  • According to the European Heart Network, each year cardiovascular disease causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union.

Possible Breakthrough in Cardiovascular Disease Diagnostics for the United States

Retrieved on: 
Friday, December 16, 2022
Peptide, Nanoparticle, Hereditary nonpolyposis colorectal cancer, SingHealth, Convergence (sustainability science), Degenerative disease, ICMR, Human services, Prostate, Biomarker, Acute coronary syndrome, Patient, Hospital, Cardiovascular disease, FDA, Dengue fever, Health, Multimedia, Coronavirus Scientific Advisory Board (Turkey), Nanotechnology, Gold, Electronics, Machine learning, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, USD, Medical research, Pharmaceutical industry, Medical imaging, Science, Myoglobin, Malaria

Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers.

Key Points: 
  • Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers.
  • The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and is currently developing effective diagnostic assays.
  • The use of small peptides, conjugated with gold nanoparticles, allows a balance of high specificity and sensitivity, giving highly accurate and fast results.
  • According to the U.S. Department of Health & Human Services, a total of 697000 people died in 2020, one person dies every 34 seconds in the US from cardiovascular disease.

Global Probiotic and Prebiotic Yogurt Market Report 2022: Increased Yogurt Consumption Worldwide Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022
Food, Beverage, Retail, Institute for Health Metrics and Evaluation, Milk, Ageing, Streptococcus thermophilus, Public Health Foundation of India, Bacteria, ICMR, Supermarket, Nutritional science, Lactic acid, Seefeld Nordic Competence Centre, BMI, Body mass index, China Health and Nutrition Survey, Medical research, Indian Council of Medical Research, Overweight, USD, Research, Streptococcus, Probiotic, Application, Yogurt, National Diet, Type 2 diabetes, Sugar, Estimation, Statistics, Evaluation, Risk, Health, Dietary supplement, Gum arabic

The "Global Probiotic and Prebiotic Yogurt Market, by Type, by Application, Estimation & Forecast, 2017-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Probiotic and Prebiotic Yogurt Market, by Type, by Application, Estimation & Forecast, 2017-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global probiotic and prebiotic yogurt market held a market value of USD 26.96 billion in 2021 and is projected to reach USD 49.76 billion by the year 2030.
  • The market volume for probiotic and prebiotic yogurt industry accounts to be 9,160.71 kilo tons in 2021, with a growth rate of 6.43% over the forecast period.
  • The market for probiotic and prebiotic yogurt is booming owing to the rising yogurt consumption, increasing research indicating the benefits of yogurt, and the rising market players.

Families in India Face Ongoing Challenges When Coping With Rare Diseases

Retrieved on: 
Monday, October 17, 2022
Quality of life, National Policy, SMA, Indian Council of Medical Research, Disease, Government, Hospital, Npistanbul Brain Hospital, Diagnosis, National Register of Historic Places, Organization, Degenerative disease, PGI, Health, Research Foundation for Governance in India, Patient, Omnichannel, Drug development, Research, ALS, Lists of diseases, Technology, MND, Department, Social stigma, ICMR, Western world, Awareness, Central Government Employees Welfare Housing Organisation, Central government, Medicine, Clinical trial, Trust, Child, EU, Observer Research Foundation, Motor neuron, Poster, Pharmaceutical industry, Medical device

HERNDON, Va., Oct. 17, 2022 /PRNewswire-PRWeb/ -- In India, an estimated 70 million people are living with a rare disease.(1) According to a recent report from RARE-X, there are about 10,867 known rare diseases in the world. Most of these maladies are debilitating, life-long, and often require costly treatments. For families supporting a loved one with a rare disease, the outcome is often bleak. Many families struggle with social stigma and limited access to specialized healthcare. Most pharmaceutical advances and treatments for rare diseases are developed in the western world, making them out of reach, even when they are available in the country, due to their abnormally high cost.

Key Points: 
  • "Every year, countless families in India struggle to provide care to family members with rare diseases.
  • For families in India, there is a great sense of urgency when it comes to the treatment of rare diseases.
  • This one-time grant for the lifelong treatment of a patient's rare disease provides financial support to patients with all three groups of rare diseases as defined in the National Policy for Rare Diseases (NPRD).
  • To learn more about the work IndoUSrare is doing to combat the challenges facing families with rare diseases in India and those in diaspora from India in the US or globally, visit https://indousrare.org .

Global Blood Transfusion Diagnostics Market Forecast to 2028 - Featuring Bio-Rad Laboratories, Abbott, Thermo Fisher Scientific and Ortho Clinical Diagnostics Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
General Health, Health, Other Health, Malaria, Indian Council of Medical Research, Chronic condition, Cancer, Hospital, Science, Ministry, News, ABC News and Current Affairs, Degenerative disease, Collection, Research, National Institute, RMIT University, Blood, Virus, CAGR, Medal of Honor (video game series), Death, COVID-19, Medical research, Growth, Blood transfusion, HIV, ICMR, Infection, Conditional sentence, Relaxation, Ministry of Health and Welfare (South Korea), Bleeding, Hepatitis B, Meta-analysis, Patient, Hepatitis C, Impact, Systematic review, Pharmaceutical industry, Medical device, Blood product, Zika fever, Application

The global blood transfusion diagnostics market is expected to grow from US$ 4,096.93 million in 2021 to US$ 6,483.75 million by 2028.

Key Points: 
  • The global blood transfusion diagnostics market is expected to grow from US$ 4,096.93 million in 2021 to US$ 6,483.75 million by 2028.
  • The growth of the global blood transfusion diagnostics market is attributed to the rapid increase in chronic diseases and the need for blood transfusion due to the rise in organ transplant surgeries.
  • Blood transfusion diagnostics refers to tests performed on blood and blood components before they are transfused to patients.
  • A blood transfusion is a common procedure in which donated blood or blood components are transfused into the patient's body through an intravenous line (IV).

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)

Retrieved on: 
Monday, May 23, 2022
People, Chemistry, Risk, Medical research, Regulation of tobacco by the U.S. Food and Drug Administration, Food, U.S. Securities and Exchange Commission, Indian Council of Medical Research, World, Biologics license application, National Institute, World Health Organization, Science, Patient, Vaccine, NASDAQ, Health, Private Securities Litigation Reform Act, Review, Clinical trial, Learning, COVID-19, Vaccination, Research, Hope, FDA, Intention, NIV, WHO, Bharat Biotech, Safety, BBV152, Health Canada, LinkedIn, Security (finance), Twitter, National Institute of Virology, Entrepreneurship, SEC, Acquisition, ICMR, CEO, Publication, NDS, GLOBE, Pharmaceutical industry

Were extremely pleased that we can proceed with our clinical trials for COVAXIN, our whole virus inactivated COVID-19 vaccine candidate.

Key Points: 
  • Were extremely pleased that we can proceed with our clinical trials for COVAXIN, our whole virus inactivated COVID-19 vaccine candidate.
  • Thank you to our clinical trial partners and site collaborators for their ongoing support.
  • Ocugen will now work with study sites to fully resume this clinical development program immediately.
  • People interested in learning about how to participate in this clinical trial (NCT05258669) can visit the clinical trials section of Ocugen.com.

Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America

Retrieved on: 
Monday, April 18, 2022
Commercialization, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Risk, NASDAQ, Research, Science, Vaccine, GLOBE, Bharat Biotech, Patient, LinkedIn, Review, Public health, Hope, Acquisition, Health, Indian Council of Medical Research, Medical research, Private Securities Litigation Reform Act, Typhoid fever, World, Partnership, Foreign Affairs, Profile, Board, COFEPRIS, National Institute of Virology, Twitter, WHO, ICMR, Vaccination, Cholera, SEC, World Health Organization, Severe acute respiratory syndrome coronavirus 2, Virus, National Institute, EUL, NIV, Emergency Use Authorization, Variant, Pharmaceutical industry, Chikungunya, Rabies, Rotavirus

MALVERN, Pa. and HYDERABAD, India, April 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, and Bharat Biotech (BBIL), a global leader in vaccine innovation, today announced that they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen’s exclusive territory to include commercialization of COVAXIN™ in Mexico. This gives Ocugen COVAXIN™ commercialization rights for all of North America.

Key Points: 
  • This gives Ocugen COVAXIN commercialization rights for all of North America.
  • Were excited to commercialize COVAXIN in Mexico, as authorities there have made conquering this pandemic a major priority.
  • As a whole virion, inactivated vaccine, it elicits robust cellular immune memory to SARS-CoV-2 and Variants of Concern.
  • Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release.

The Worldwide Immune Health Products Industry is Expected to Reach $28.9 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 30, 2022
General Health, Health, Fitness & Nutrition, CAGR, USD, ICMR, Sale, Form, International Diabetes Federation, Diabetes, Growth, Market share, Evaluation, Sciatica, Incidence, Cancer, Institute for Health Metrics and Evaluation, Arthritis, Counterfeit, Immunity, Medical research, Prevalence, Micronutrient, Industry, Vitamin, Chronic pain, Function, Institute, Public Health Foundation of India, Type 2 diabetes, Indian Council of Medical Research, Internet, Estimation, Process state, Dietary supplement, Vaccine

The global immune health products market held a market value of USD 15,607.6 million in 2020 and is projected to reach USD 28,996.3 million by the year 2027.

Key Points: 
  • The global immune health products market held a market value of USD 15,607.6 million in 2020 and is projected to reach USD 28,996.3 million by the year 2027.
  • Immune health products boost the immunity of an individual by providing the necessary vitamins, mineral, and micronutrients to the body.
  • In contrast to that, the immune health products market is likely to get curbed due to an increase in the number of counterfeit drugs sold in the industry.
  • The global immune health products market is segmented into source, processed state, type, form, function, and distribution channel.

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

Retrieved on: 
Friday, February 18, 2022
NASDAQ, Private Securities Litigation Reform Act, GSK, Patient, Food, EUA, ICMR, Typhoid fever, Indian Council of Medical Research, Bharat Biotech, Diabetic retinopathy, Risk, NIV, SEC, Rabies, U.S. Securities and Exchange Commission, Review, Vaccine, World, BBV152, Security (finance), Chemistry, IND, COVAXIN, Clinical trial, Health Canada, Safety, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Medical research, National Institute of Virology, WHO, FDA, Publication, Board, Acquisition, Research, Retina, BLA, World Health Organization, COVID-19, Vaccination, GLOBE, National Institute, Pharmaceutical industry, GlaxoSmithKline, Rotavirus, Chikungunya, Zika fever

COVAXIN is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.

Key Points: 
  • COVAXIN is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.
  • COVAXIN (BBVI52) is an investigational vaccine candidate product in the U.S.
  • It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) National Institute of Virology (NIV).
  • COVAXIN is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.